
This image depicts the structure of the BAX protein (purple). The activator compound BTSA1 (orange) has bound to the active site of BAX (green), changing the shape of the BAX molecule at several points (shown in yellow, magenta and cyan). BAX, once in its final activated form, can home in on mitochondria and puncture their outer membranes, triggering apoptosis (cell death).
Scientists at Albert Einstein College of Medicine have discovered the first compound that directly makes cancer cells commit suicide while sparing healthy cells. The new treatment approach, described in today’s issue of Cancer Cell, was directed against acute myeloid leukemia (AML) cells but may also have potential for attacking other types of cancers.
“We’re hopeful that the targeted compounds we’re developing will prove more effective than current anti-cancer therapies by directly causing cancer cells to self-destruct,” says Evripidis Gavathiotis, Ph.D., associate professor of biochemistry and of medicine and senior author of the study. “Ideally, our compounds would be combined with other treatments to kill cancer cells faster and more efficiently—and with fewer adverse effects, which are an all-too-common problem with standard chemotherapies.”
AML accounts for nearly one-third of all new leukemia cases and kills more than 10,000 Americans each year. The survival rate for patients has remained at about 30 percent for several decades, so better treatments are urgently needed.
The newly discovered compound combats cancer by triggering apoptosis—an important process that rids the body of unwanted or malfunctioning cells. Apoptosis trims excess tissue during embryonic development, for example, and some chemotherapy drugs indirectly induce apoptosis by damaging DNA in cancer cells.
Apoptosis occurs when BAX—the “executioner protein” in cells—is activated by “pro-apoptotic” proteins in the cell. Once activated, BAX molecules home in on and punch lethal holes in mitochondria, the parts of cells that produce energy. But all too often, cancer cells manage to prevent BAX from killing them. They ensure their survival by producing copious amounts of “anti-apoptotic” proteins that suppress BAX and the proteins that activate it.
“Our novel compound revives suppressed BAX molecules in cancer cells by binding with high affinity to BAX’s activation site,” says Dr. Gavathiotis. “BAX can then swing into action, killing cancer cells while leaving healthy cells unscathed.”
Dr. Gavathiotis was the lead author of a 2008 paper in Nature that first described the structure and shape of BAX’s activation site. He has since looked for small molecules that can activate BAX strongly enough to overcome cancer cells’ resistance to apoptosis. His team initially used computers to screen more than one million compounds to reveal those with BAX-binding potential. The most promising 500 compounds—many of them newly synthesized by Dr. Gavathiotis’ team—were then evaluated in the laboratory.
“A compound dubbed BTSA1 (short for BAX Trigger Site Activator 1) proved to be the most potent BAX activator, causing rapid and extensive apoptosis when added to several different human AML cell lines,” says lead author Denis Reyna, M.S., a doctoral student in Dr. Gavathiotis’ lab. The researchers next tested BTSA1 in blood samples from patients with high-risk AML. Strikingly, BTSA1 induced apoptosis in the patients’ AML cells but did not affect patients’ healthy blood-forming stem cells.
Finally, the researchers generated animal models of AML by grafting human AML cells into mice. BTSA1 was given to half the AML mice while the other half served as controls. On average, the BTSA1-treated mice survived significantly longer (55 days) than the control mice (40 days), with 43 percent of BTSA1-treated AML mice alive after 60 days and showing no signs of AML.
Importantly, the mice treated with BTSA1 showed no evidence of toxicity. “BTSA1 activates BAX and causes apoptosis in AML cells while sparing healthy cells and tissues—probably because the cancer cells are primed for apoptosis,” says Dr. Gavathiotis. He notes that his study found that AML cells from patients contained significantly higher BAX levels compared with normal blood cells from healthy people. “With more BAX available in AML cells,” he explained, “even low BTSA1 doses will trigger enough BAX activation to cause apoptotic death, while sparing healthy cells that contain low levels of BAX or none at all.”
Plans call for Dr. Gavathiotis and his team to see whether BTSA1 will show similar effectiveness when tested on animal models of other types of cancer.
Learn more: Novel Treatment Causes Cancer to Self-Destruct Without Affecting Healthy Cells
The Latest on: Cancer cells commit suicide
[google_news title=”” keyword=”cancer cells commit suicide” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- What are cancer-fighting foods?on March 19, 2023 at 5:00 pm
One 2018 study suggests that apple phloretin significantly inhibits the growth of breast cancer cells while not affecting healthy cells. This polyphenol inhibits a protein called glucose ...
- How cancer cells repair DNA damage induced by next-generation radiotherapyon March 16, 2023 at 2:34 pm
therapy is frequently used in the treatment of cancer and is believed to destroy cancer cells by inducing DNA breaks. The newest type of radiation therapy harnesses radiation produced by a ...
- A Spotlight on Cancer Cell Metabolismon March 14, 2023 at 10:25 pm
Cancer cells possess different metabolic properties from healthy cells, and these differences drive many of the mechanisms—such as proliferation, tumor development, and metastasis—that make cancer so ...
- Using antagonistic drug combinations for selective killing of resistant cancer cellson March 13, 2023 at 5:00 pm
A new review paper was published in Oncotarget's Volume 14 on March 11, 2023, entitled, "Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells.
- Does Immunotherapy for Lung Cancer Work?on March 9, 2023 at 4:00 pm
Immunotherapy may help improve the survival rate for people with certain forms of lung cancer. Many of these drugs are undergoing clinical trials. Immunotherapy is a treatment used for some forms ...
- How Immunotherapy for Cancer Workson March 9, 2023 at 4:00 pm
So are vaccines for diseases like measles and mumps. How does that relate to cancer? The disease starts when one cell in your body goes rogue. Researchers hope immunotherapy treatment will harness ...
- Bacterial ‘suicide squads’ engineered to find tumours and alert body’s immune systemon March 9, 2023 at 6:46 am
Scientists have genetically engineered bacteria into “suicide ... types of immune cells and stimulating them to respond in various ways. READ MORE: Woman, 30, hit with cancer after spotting ...
- Everything to know about non-small cell lung canceron March 6, 2023 at 4:00 pm
Non-small cell lung cancer is an umbrella term that describes several lung cancers. Several treatment options are available, and early diagnosis can improve a person’s outlook. Non-small cell ...
- Local veteran is raising awareness for veteran suicide, all while battling canceron March 3, 2023 at 10:31 am
A local veteran battling cancer is raising money to help prevent veteran suicide by participating in the 48-mile Ruck March Challenge for Mission 22. Fran Gray says he recently finished his first ...
- Chemotherapy-resistant ovarian cancer cells protect their neighborson March 3, 2023 at 6:33 am
Certain chemotherapy-resistant ovarian cancer cells protect neighboring cancer cells by sending signals that induce resistance, according to a new study from University of Pittsburgh and UPMC ...
via Google News and Bing News